Voyager Therapeutics, Inc. (VYGR) saw its loss widen to $9 million, or $0.35 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $3.92 million, or $5.25 a share.
Revenue during the quarter plunged 33 percent to $3.31 million from $4.94 million in the previous year period.
Operating loss for the quarter was $10.37 million, compared with an operating loss of $4.02 million in the previous year period.
"Voyager has made significant progress this quarter with its lead and pipeline programs and business development activities," said Steven Paul, M.D., president and chief executive officer of Voyager Therapeutics. "During the third quarter, we continued to enroll patients in our ongoing, dose-ranging Phase 1b trial of VY-AADC01 in advanced Parkinson's disease. We remain on track to report top-line, interim safety and efficacy data from Cohorts 1 and 2 in early December. Our pipeline of AAV gene therapy programs continued to advance during the quarter, and we have expanded our portfolio of novel AAV capsids through a recent licensing agreement with the California Institute of Technology for capsids which have demonstrated in preclinical models markedly enhanced blood-brain barrier penetration for the potential treatment of CNS diseases."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
